JP2014501505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501505A5 JP2014501505A5 JP2013539992A JP2013539992A JP2014501505A5 JP 2014501505 A5 JP2014501505 A5 JP 2014501505A5 JP 2013539992 A JP2013539992 A JP 2013539992A JP 2013539992 A JP2013539992 A JP 2013539992A JP 2014501505 A5 JP2014501505 A5 JP 2014501505A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cell
- polyclonal
- population
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 179
- 238000000034 method Methods 0.000 claims description 151
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 93
- 239000013598 vector Substances 0.000 claims description 56
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 108091008874 T cell receptors Proteins 0.000 claims description 22
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 22
- 230000001177 retroviral effect Effects 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 12
- 102100034343 Integrase Human genes 0.000 claims description 12
- 108010061833 Integrases Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
- 108010084455 Zeocin Proteins 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229930189065 blasticidin Natural products 0.000 claims description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 4
- 229950010131 puromycin Drugs 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 3
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 3
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 3
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 3
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims description 3
- 239000013607 AAV vector Substances 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 102000018120 Recombinases Human genes 0.000 claims description 2
- 108010091086 Recombinases Proteins 0.000 claims description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 238000002523 gelfiltration Methods 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41422510P | 2010-11-16 | 2010-11-16 | |
| US61/414,225 | 2010-11-16 | ||
| PCT/US2011/061092 WO2012068317A2 (en) | 2010-11-16 | 2011-11-16 | Methods for producing recombinant proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501505A JP2014501505A (ja) | 2014-01-23 |
| JP2014501505A5 true JP2014501505A5 (enExample) | 2015-01-08 |
| JP6092782B2 JP6092782B2 (ja) | 2017-03-08 |
Family
ID=45406837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539992A Expired - Fee Related JP6092782B2 (ja) | 2010-11-16 | 2011-11-16 | 組換えタンパク質の製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8617881B2 (enExample) |
| EP (1) | EP2640743B1 (enExample) |
| JP (1) | JP6092782B2 (enExample) |
| AU (1) | AU2011329872B2 (enExample) |
| CA (1) | CA2817751C (enExample) |
| DK (1) | DK2640743T3 (enExample) |
| WO (1) | WO2012068317A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7095994B2 (ja) | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
| TWI554608B (zh) * | 2015-03-27 | 2016-10-21 | Univ China Medical | A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| EP3810649A1 (en) | 2018-06-22 | 2021-04-28 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| AU2022291273A1 (en) * | 2021-06-10 | 2024-01-25 | Janssen Biotech, Inc. | Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| US5686120A (en) | 1995-05-22 | 1997-11-11 | Wisconsin Alumni Research Foundation | Pre-mRNA processing enhancer and method for intron-independent gene expression |
| BR9808584A (pt) | 1997-03-14 | 2000-05-23 | Idec Pharma Corp | Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| AU6364800A (en) | 1999-07-23 | 2001-02-13 | Regents Of The University Of California, The | Dna recombination in eukaryotic cells by the bacteriophage phic31 recombination system |
| AU2001271614B2 (en) | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
| CA2413156C (en) | 2000-07-03 | 2009-08-18 | Gala Design, Inc. | Expression vectors |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| CA2512647C (en) * | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| ES2785223T3 (es) * | 2006-06-21 | 2020-10-06 | Uniqure Ip Bv | Células de insecto para la producción de vectores de AAV |
| HRP20100640T1 (hr) * | 2007-05-25 | 2010-12-31 | Symphogen A/S | Postupak proizvodnje rekombinantnog poliklonskog proteina |
| CA2722348A1 (en) * | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
-
2011
- 2011-11-16 DK DK11801886.0T patent/DK2640743T3/en active
- 2011-11-16 WO PCT/US2011/061092 patent/WO2012068317A2/en not_active Ceased
- 2011-11-16 CA CA2817751A patent/CA2817751C/en active Active
- 2011-11-16 AU AU2011329872A patent/AU2011329872B2/en active Active
- 2011-11-16 JP JP2013539992A patent/JP6092782B2/ja not_active Expired - Fee Related
- 2011-11-16 EP EP11801886.0A patent/EP2640743B1/en active Active
-
2012
- 2012-06-13 US US13/495,993 patent/US8617881B2/en active Active
-
2013
- 2013-09-26 US US14/037,833 patent/US9447174B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jian et al. | Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN. 1 | |
| JP2023538891A5 (enExample) | ||
| Phad et al. | Clonal structure, stability and dynamics of human memory B cells and circulating plasmablasts | |
| Younis et al. | Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus | |
| Sjöberg et al. | Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling | |
| US20230134868A1 (en) | Biomagnetic microsphere and preparation method therefor and use thereof | |
| Martin et al. | Epigenetic features of HIV-induced T-cell exhaustion persist despite early antiretroviral therapy | |
| JP2011504721A (ja) | 組み換えポリクローナルタンパク質を製造する方法 | |
| JP2014506790A5 (enExample) | ||
| JP2018148915A5 (enExample) | ||
| Kreer et al. | Exploiting B cell receptor analyses to inform on HIV-1 vaccination strategies | |
| WO2011109726A2 (en) | Homologous multi-specific antibodies | |
| WO2014205344A2 (en) | Virion display array for profiling functions and interactions of human membrane proteins | |
| Niu et al. | Longitudinal analysis of the antibody repertoire of a Zika virus-infected patient revealed dynamic changes in antibody response | |
| JPWO2023282161A5 (enExample) | ||
| Lomakin et al. | Two-dimensional high-throughput on-cell screening of immunoglobulins against broad antigen repertoires | |
| Tevelev et al. | Genetic rearrangement during site specific integration event facilitates cell line development of a bispecific molecule | |
| Blengio et al. | Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26. ZEBOV/MVA-BN-Filo | |
| Mirian et al. | Generation of HBsAg DNA aptamer using modified cell-based SELEX strategy | |
| CN110878124B (zh) | Dna聚合酶的抗体片段、抗体及其应用 | |
| Bruun et al. | Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins | |
| WO2018011584A1 (en) | Kit for amplifying immunoglobulin sequences | |
| Leavitt et al. | Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120 | |
| Sun et al. | Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naive B-cell library | |
| Grimm et al. | Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies |